Restricted Uses Without limiting the unsupported or prohibited use cases identified in the Stripe Identity Permitted Businesses list, you must not, and must not enable or allow any other party to: (a) modify the Stripe Identity Services in any way, including by changing
Permitted Uses BA shall use Protected Information only for the purpose of performing BA’s obligations under the Contract and as permitted or required under the Contract and Addendum, or as required by law. Further, BA shall not use Protected Information in any manner that would constitute a violation of the Privacy Rule or the HITECH Act if so used by CE. However, BA may use Protected Information as necessary (i) for the proper management and administration of BA;
Restricted Use Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments (Various) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.
Permitted and Prohibited Uses 1.1. The Data may only be used for linguistic education and research, including but not limited to information retrieval, document understanding, machine translation or speech recognition. 1.2. User shall not publish, retransmit, display, redistribute, reproduce or commercially exploit the Data in any form, except that User may include limited excerpts from the Data in articles, reports and other documents describing the results of User’s linguistic education and research.
Permitted Use (a) Tenant shall, at all times during the Term, and at any other time that Tenant shall be in possession of any Property, continuously use and operate, or cause to be used and operated, such Property as a skilled nursing/ intermediate care/independent living/assisted living/ special care/group home facility as currently operated, and any uses incidental thereto. Tenant shall not use (and shall not permit any Person to use) any Property, or any portion thereof, for any other use without the prior written consent of Landlord, which approval shall not be unreasonably withheld, delayed or conditioned. No use shall be made or permitted to be made of any Property and no acts shall be done thereon which will cause the cancellation of any insurance policy covering such Property or any part thereof (unless another adequate policy is available) or which would constitute a default under any ground lease affecting such Property, nor shall Tenant sell or otherwise provide to residents or patients therein, or permit to be kept, used or sold in or about any Property any article which may be prohibited by law or by the standard form of fire insurance policies, or any other insurance policies required to be carried hereunder, or fire underwriter’s regulations. Tenant shall, at its sole cost (except as expressly provided in Section 5.1.2(b)), comply or cause to be complied with all Insurance Requirements. Tenant shall not take or omit to take, or permit to be taken or omitted to be taken, any action, the taking or omission of which materially impairs the value or the usefulness of any Property or any part thereof for its Permitted Use. (b) In the event that, in the reasonable determination of Tenant, it shall no longer be economically practical to operate any Property as currently operated, Tenant shall give Landlord Notice thereof, which Notice shall set forth in reasonable detail the reasons therefor. Thereafter, Landlord and Tenant shall negotiate in good faith to agree on an alternative use for such Property, appropriate adjustments to the Additional Rent and other related matters; provided, however, in no event shall the Minimum Rent be reduced or abated as a result thereof. If Landlord and Tenant fail to agree on an alternative use for such Property within sixty (60) days after commencing negotiations as aforesaid, Tenant may market such Property for sale to a third party. If Tenant receives a bona fide offer (an “Offer”) to purchase such Property from a Person having the financial capacity to implement the terms of such Offer, Tenant shall give Landlord Notice thereof, which Notice shall include a copy of the Offer executed by such third party. In the event that Landlord shall fail to accept or reject such Offer within thirty (30) days after receipt of such Notice, such Offer shall be deemed to be rejected by Landlord. If Landlord shall sell the Property pursuant to such Offer, then, effective as of the date of such sale, this Agreement shall terminate with respect to such Property, and the Minimum Rent shall be reduced by an amount equal to the product of the net proceeds of sale received by Landlord multiplied by the Interest Rate. If Landlord shall reject (or be deemed to have rejected) such Offer, then, effective as of the proposed date of such sale, this Agreement shall terminate with respect to such Property, and the Minimum Rent shall be reduced by an amount equal to the product of the projected net proceeds determined by reference to such Offer multiplied by the Interest Rate.